Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Employers, health plans trying various remedies for soaring drug costs.(News)
- Byline: ROBERTO CENICEROS Employers, health plans and pharmaceutical benefit managers are all implementing a variety of measures to help hold down escalating prescription drug expenses. Their efforts-including benefit design changes, co-payment Byline: ROBERTO CENICEROS Employers, health plans...
- Research articles 2003-06-30
- PhRMA Opposes Drug Import Amendment in 2001 Spending Bill.(Brief Article)
- WHILE PHARMACEUTICAL manufacturers continue to oppose efforts to create a new Medicare drug benefit that could lead to price controls, the industry is also furiously lobbying against a more immediate concern: a drug-import provision in both the Hou WHILE PHARMACEUTICAL manufacturers continue to oppose...
- Research articles 2000-08-28
- Drug Import Legislation Is Urged.(Brief Article)
- The pharmaceutical industry sees the measure as a disguised price control. A SENATE Democrat is urging his cob leagues to support legislation that would allow imports of lower-priced prescription drugs identical to those sold in the US. ...
- Research articles 2000-06-26
- Drug Reimportation Bill On the Way to White House.(Brief Article)
- DESPITE STRONG opposition by the pharmaceutical industry, legislation establishing a prescription drug reimportation system is on its way to the White House, where President Clinton is expected sign it into law. The measure would let pharmaci DESPITE STRONG...
- Research articles 2000-10-30
- Administration proposes pro-generics rule changes.(White House proposes to block brand-name drug companies from filing multiple patent-protection lawsuits)
- THE WHITE HOUSE proposed new regulations last week that would make it easier for generic drugs to reach the market by blocking brand-name pharmaceutical companies from filing multiple patent-protection lawsuits. "I'm taking action to clo THE WHITE HOUSE...
- Research articles 2002-10-28
- Competition: An Antidote to the High Price of Prescription Drugs
- Patent protection and factors unique to prescription drugs weaken the forces keeping prices near costs for other products. A growing public consensus that affordable drugs should be available to all is likely to increase the upward pressure on prices. To restore competition to all parts of the pharmaceutical industry, this...
- White papers 2004-08-01
Additional Resources
- Maker of OxyContin to Fund Campaign to Prevent Teen Prescription Drug Abuse.
- By Selena Ricks, Portland Press Herald, Maine Knight Ridder/Tribune Business News Jun. 19--The maker of OxyContin plans to announce today it will fund an education campaign combating prescription drug abuse among teenagers. The company, Purdue Pharma, says this is the...
- Research articles 2003-06-19
- Astellas Pharma US, Inc. Selects Dendrite for Sample Compliance Solutions; Dendrite's Robust and Intuitive Compliance Solutions Chosen to Increase Regulatory Compliance and Accountability of Prescription Drug Samples
- BEDMINSTER, N.J. -- Dendrite International, Inc., (NASDAQ: DRTE) a leading provider of pharmaceutical industry solutions, today announced that Astellas Pharma US, Inc., a pharmaceutical company dedicated to improving the health of populations around the world, signed a three-year contract to outsource its sample accountability and compliance processes to Dendrite. ...
- Research articles 2006-08-14
- Drug Makers Gave Lobbyists an Xmas Gift -- Millions More to Lobby Obama Administration
- A New Year will bring a new president, a new FDA chief, many new drug regulations, and, possibly, health insurance reform. Mindful of the ton of major drug brands that will go off-patent in 2009, drug companies have not rested in their lobbying efforts over generics and patent issues. They...
- Blog posts 2008-12-31
- ProEthic Pharmaceuticals Announces Acceptance of New Drug Application for Migraine
- MONTGOMERY, Ala. -- ProEthic Pharmaceuticals, Inc., a privately funded specialty pharmaceutical company that acquires, develops, licenses and markets niche prescription products, announced today that the U.S. Food and Drug Administration FDA has accepted the Company's submission of its New Drug Application for PRO-513 for the treatment of migraine headaches. In...
- Research articles 2007-12-12
- Man Bites Dog: Former Merck CEO Blasts High Drug Prices
- Most pharmaceutical companies insist that high drug prices are a natural consequence of the risky business of drug discovery, and that huge profits on marketed drugs are necessary to cover the costs of the 5,000 to 10,000 experimental drugs that fail for every one that succeeds. In fact, there are...
- Blog posts 2008-05-05
- J&J Profit Beats Estimates, But Sales Fall Short
- By Ransdell Pierson and Lewis Krauskopf NEW YORK (Reuters) - Johnson & Johnson JNJ posted weaker-than-expected quarterly revenue on Tuesday as sales of prescription drugs and cardiac stents disappointed, sending its shares down more than 2 percent. While third-quarter profit topped analyst forecasts, that was largely because of cost cuts...
- News items 2009-10-13
- Low-Income Oregon Residents Navigate Drug Company Programs.
- By Patrick O'Neill, The Oregonian, Portland, Ore. Knight Ridder/Tribune Business News Mar. 12--Sick, low-income Oregonians are scrambling for prescription medicines offered free through a maze of programs sponsored by pharmaceutical companies. The programs are a godsend to many who...
- Research articles 2003-03-12
- Company Profile for Cypress Pharmaceutical, Inc
- Cypress Pharmaceutical, Inc. ("Cypress" or the "Company"), founded in 1993, is a rapidly growing specialty pharmaceutical company that develops, markets and distributes generic prescription pharmaceutical products to the leading national pharmaceutical wholesalers, chain drug stores, distributors, and other retail merchandisers. In 1999, Cypress established a specialty branded business; Hawthorn Pharmaceuticals...
- Research articles 2008-01-18
- Warner Chilcott pays $3.1B for P&G drug unit
- Late last year, Proctor & Gamble decided that it wanted out of the pharmaceuticals business. Its drug unit--which features drugs in the areas of women's health, gastrointestinal problems and musculoskeletal disorders--had not been very profitable for P&G, so the company went hunting for a buyer. After months of searching, Warner Chlcott...
- News items 2009-08-24
- Consumer Group Demands Merck Disclose Amount of Executive Payouts; Golden Parachutes Cost Seniors & Patients in Higher Drug Prices
- SANTA MONICA, Calif., Nov. 30 /U.S. Newswire/ -- A consumer group demanded today that pharmaceutical giant Merck disclose how much money it plans to pay top executives if the company is taken over and how those payouts will affect prescription drug pricesSANTA MONICA, Calif., Nov. 30 /U.S. Newswire/ -- A...
- Research articles 2004-11-30
- SinoFresh Makes Progress Toward Attracting Pharmaceutical Partner to Co-Develop and Market Prescription Nasal Spray
- SinoFresh HealthCare, Inc. (OTC BB: SFSH), through its partnership with CAM-Global, a business development firm specializing in assisting companies to evaluate and execute upon growth and expansion opportunities, announced that it is making progress towards attracting a pharmaceutical company to co-develop and market a prescription version of its patented nasal...
- Research articles 2005-10-04
- Santarus Announces FDA Acceptance of New Drug Application For ZEGERID Capsules; FDA Action Expected in Early 2006 on NDA for First Immediate-Release Proton Pump Inhibitor in Capsule Formulation
- SAN DIEGO -- Santarus, Inc. (Nasdaq:SNTS), a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, today announced that the U.S. Food and Drug Administration FDA has accepted for filing the company's New Drug Application NDA for ZEGERIDR omeprazole Capsules 40 mg and 20 mg. Pursuant to Prescription...
- Research articles 2005-06-28
- Santarus Announces FDA Acceptance of New Drug Application For ZEGERID Chewable Tablets
- SAN DIEGO -- Santarus, Inc. (Nasdaq:SNTS), a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, today announced that the U.S. Food and Drug Administration FDA has accepted for filing the company's New Drug Application NDA for ZEGERIDR omeprazole Chewable Tablets 40 mg and 20 mg. Pursuant to...
- Research articles 2005-07-26
- Lilly Profit Tops Estimates on Drug Sales, Taxes
- By Lewis Krauskopf NEW YORK (Reuters) - Eli Lilly and Co LLY posted third-quarter profit well above Wall Street expectations on Wednesday on strong performance of its major prescription drugs and lower taxes, sending shares up 1.9 percent. Sales of lung cancer treatment Alimta, anti-depressant Cymbalta, Humalog insulin and schizophrenia...
- News items 2009-10-21
- << Previous
- page 1 of 1
- Next >>
